The treatment of multiple sclerosis (MS) has evolved remarkably over the past 25 years. This progress has been enabled by advances in research, drug development and active engagement of the scientific community with regulatory authorities. However, an inconsistent approach to MS disease courses could have a negative impact on the drug development process.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Central nervous system regeneration: the roles of glial cells in the potential molecular mechanism underlying remyelination
Inflammation and Regeneration Open Access 02 March 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
[No authors listed.] FDA approves new drug to treat multiple sclerosis. US Food and Drug Administration https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm549325.htm (2017).
[No authors listed.] New medicine for multiple sclerosis. European Medicines Agency http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2017/11/news_detail_002847.jsp&mid=WC0b01ac058004d5c1 (2017).
Lublin, F. D. et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83, 278–286 (2014).
Committee for Medicinal Products for Human Use (CHMP). Guideline on Clinical Investigation of Medicinal Products for the Treatment of Multiple Sclerosis (European Medicines Agency, 2015).
U.S. Food and Drug Administration. Ocrelizumab Summary Review. US Food and Drug Administration https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761053Orig1s000SumR.pdf (2017).
Acknowledgements
A.J.T. acknowledges support from the UCL/UCLH National Institute of Health (NIHR) Biomedical Research Centre (BRC).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
A.J.T. is chair and T.C. a member of the International Progressive MS Alliance Scientific Steering Committee.
Rights and permissions
About this article
Cite this article
Coetzee, T., Thompson, A. Unified understanding of MS course is required for drug development. Nat Rev Neurol 14, 191–192 (2018). https://doi.org/10.1038/nrneurol.2017.184
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2017.184
This article is cited by
-
Central nervous system regeneration: the roles of glial cells in the potential molecular mechanism underlying remyelination
Inflammation and Regeneration (2022)